NYU Langone's Perlmutter Cancer Center | Strategic Alliance Partners

January 23, 2017

Franco M. Muggia, MD, discusses the results of the Gynecologic Oncology Group (GOG) 252 trial and what the findings mean regarding intraperitoneal therapy for patients with ovarian cancer.

January 06, 2017

Franco M. Muggia, MD, professor, Department of Medicine, NYU Langone Medical Center, discusses the current challenges oncologists are facing in the treatment landscape of ovarian cancer.

January 02, 2017

In recent years, advancements in the treatment of patients with metastatic melanoma have proceeded in 2 areas: targeted therapies and immunotherapies.

December 23, 2016

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the risks and benefits of combination immunotherapy as treatment for patients with melanoma.

December 20, 2016

Anna C. Pavlick, DO, medical oncologist, NYU Langone School of Medicine, discusses ongoing clinical trials exploring treatment with immunotherapy in patients with basal cell carcinoma as well as squamous cell carcinoma.

December 07, 2016

When combined with psychological counseling, a single dose of a mind-altering compound contained in psychedelic mushrooms significantly lessens mental anguish in distressed cancer patients for months at a time, according to results of a clinical trial led by researchers at NYU Langone Medical Center.

November 28, 2016

Significant progress is being made in the treatment of gynecologic malignancies, especially in ovarian cancer, according to Douglas A. Levine, MD.

October 06, 2016

The Perlmutter Cancer Center at NYU Langone Medical Center has named noted clinician-scientist Kwok-Kin Wong, MD, PhD, as its new Chief of Hematology and Medical Oncology.

October 05, 2016

Jeffery S. Weber, MD, PhD, deputy director of the Laura and Isaac Perlmutter Cancer Center, co-director of the Melanoma Program, and head of Experimental Therapeutics at NYU Langone Medical Center, discusses considering factors when selecting an immunotherapy agent for a patient with melanoma.

October 04, 2016

Using a "one-drug-fits-all" approach is not going to be a successful paradigm in a complex disease like glioblastoma.

September 07, 2016

Francisco J. Esteva, MD, PhD, medical oncologist, New York Langone Medical Center, discusses the importance of having a clinical trial of the trastuzumab (Herceptin) biosimilar MYL-1401O for patients with HER2-positive breast cancer.

August 09, 2016

Jeffery S. Weber, MD, PhD, discusses findings from the phase II CheckMate-064 trial, in which patients were randomized to receive either nivolumab followed by ipilimumab followed by nivolumab maintenance therapy, or ipilimumab followed by nivolumab and maintenance therapy with nivolumab.

August 05, 2016

Brian L. Schmidt, DDS, MD, PhD, discusses the difficulties of studying cancer pain and developing new drugs.

June 29, 2016

Potential to render cancer cells less able to cope with hypoxia.

April 26, 2016

The presence of certain bacteria in the mouth may reveal increased risk for pancreatic cancer and enable earlier, more precise treatment. This is the main finding of a study led by researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center.

April 26, 2016

Melanoma, mesothelioma are the focus of first joint studies.

April 26, 2016

New findings could lead to anti-cancer drug developments that reverse immunosuppressive environments.

April 17, 2016

The American Association for Cancer Research has announced that Dafna Bar-Sagi, PhD, senior vice president and vice dean for science and chief scientific officer at NYU Langone, has been named to its Board of Directors for a three-year term formally commencing at the AACR’s annual meeting April 16-20, 2016.

April 06, 2016

Deirdre J. Cohen, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses emerging agents for the treatment of patients with gastric cancer.

March 30, 2016

Renewing a commitment to advance its reputation in lung cancer and other thoracic malignancies, NYU Langone Medical Center has announced the appointment of physician-scientist Leena Gandhi, MD, PhD, as director of thoracic medical oncology at its Laura and Isaac Perlmutter Cancer Center.